Eli Lilly $4 billion notes offering
The investment-grade notes are due 2026, 2033, 2053 and 2063
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
CStone Pharmaceuticals HK$392.9 million placing of new shares
We advised CStone Pharmaceuticals on the placement
CureVac $250 million follow-on offering
We advised CureVac on the equity offering
RxSight $50 million follow-on offering
The stock is listed on the Nasdaq Global Market
Elevance Health $2.6 billion senior notes offering
The investment-grade notes are due 2026, 2033 and 2053
ADC Therapeutics secondary offering
We advised ADC Therapeutics on the registered secondary offering of its shares
Roivant Sciences $230 million stock offering
We advised the company on its SEC-registered offering
Integer Holdings $500 million convertible senior notes offering
The 2.125% convertible notes are due 2028
Pacific Biosciences $201.25 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Precigen $75 million follow-on offering
We advised Precigen on the SEC-registered offering